Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


CRISPR-engineered T cells in patients with refractory cancer.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.

Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print]


CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.

Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA.

Hum Vaccin Immunother. 2019;15(5):1126-1132. doi: 10.1080/21645515.2019.1571893. Epub 2019 Apr 2.


Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH.

Mol Ther. 2018 Jan 3;26(1):269-279. doi: 10.1016/j.ymthe.2017.10.012. Epub 2017 Oct 20.


Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat.

Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J.

Mol Cell Biol. 2014 Jun;34(11):1911-28. doi: 10.1128/MCB.01013-13. Epub 2014 Mar 17.


The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytes.

Funderburg NT, Jadlowsky JK, Lederman MM, Feng Z, Weinberg A, Sieg SF.

Immunology. 2011 Oct;134(2):151-60. doi: 10.1111/j.1365-2567.2011.03475.x.


Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, Riddick NE, Mercanti V, Hartley O, Lederman MM.

Blood. 2011 Jul 28;118(4):1015-9. doi: 10.1182/blood-2010-05-282509. Epub 2010 Nov 10.


Dominant negative mutant cyclin T1 proteins that inhibit HIV transcription by forming a kinase inactive complex with Tat.

Jadlowsky JK, Nojima M, Okamoto T, Fujinaga K.

J Gen Virol. 2008 Nov;89(Pt 11):2783-7. doi: 10.1099/vir.0.2008/002857-0.


Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat.

Jadlowsky JK, Nojima M, Schulte A, Geyer M, Okamoto T, Fujinaga K.

Retrovirology. 2008 Jul 11;5:63. doi: 10.1186/1742-4690-5-63.

Supplemental Content

Loading ...
Support Center